SA523440745B1 - (TfR1) ربائط الببتيد ثنائية الحلقة الخاصة بمستقبلات الترانسفيرين 1 - Google Patents

(TfR1) ربائط الببتيد ثنائية الحلقة الخاصة بمستقبلات الترانسفيرين 1

Info

Publication number
SA523440745B1
SA523440745B1 SA523440745A SA523440745A SA523440745B1 SA 523440745 B1 SA523440745 B1 SA 523440745B1 SA 523440745 A SA523440745 A SA 523440745A SA 523440745 A SA523440745 A SA 523440745A SA 523440745 B1 SA523440745 B1 SA 523440745B1
Authority
SA
Saudi Arabia
Prior art keywords
tfr1
binding complexes
peptide ligands
unit binding
transferrin receptor
Prior art date
Application number
SA523440745A
Other languages
Arabic (ar)
English (en)
Inventor
مود جيما
سكينير مايكل
غوانز إلين
سيث بونيت
ستانواي ستيفين
ريجبي مايكل
فان ريتشوتن كاترين
أوربوناس ليودفيكاس
Original Assignee
بايسيكل تي اكس ليمتد
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Priority claimed from GBGB2017927.1A external-priority patent/GB202017927D0/en
Priority claimed from GBGB2106903.4A external-priority patent/GB202106903D0/en
Application filed by بايسيكل تي اكس ليمتد filed Critical بايسيكل تي اكس ليمتد
Publication of SA523440745B1 publication Critical patent/SA523440745B1/ar

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/54—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound
    • A61K47/55—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being an organic compound the modifying agent being also a pharmacologically or therapeutically active agent, i.e. the entire conjugate being a codrug
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K47/00—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient
    • A61K47/50—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates
    • A61K47/51—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent
    • A61K47/62—Medicinal preparations characterised by the non-active ingredients used, e.g. carriers or inert additives; Targeting or modifying agents chemically bound to the active ingredient the non-active ingredient being chemically bound to the active ingredient, e.g. polymer-drug conjugates the non-active ingredient being a modifying agent the modifying agent being a protein, peptide or polyamino acid
    • A61K47/64—Drug-peptide, drug-protein or drug-polyamino acid conjugates, i.e. the modifying agent being a peptide, protein or polyamino acid which is covalently bonded or complexed to a therapeutically active agent
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K1/00—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length
    • C07K1/107—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides
    • C07K1/1072—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups
    • C07K1/1075—General methods for the preparation of peptides, i.e. processes for the organic chemical preparation of peptides or proteins of any length by chemical modification of precursor peptides by covalent attachment of residues or functional groups by covalent attachment of amino acids or peptide residues
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/04—Linear peptides containing only normal peptide links
    • C07K7/08—Linear peptides containing only normal peptide links having 12 to 20 amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K7/00—Peptides having 5 to 20 amino acids in a fully defined sequence; Derivatives thereof
    • C07K7/64—Cyclic peptides containing only normal peptide links
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides

Landscapes

  • Chemical & Material Sciences (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Engineering & Computer Science (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Molecular Biology (AREA)
  • Biochemistry (AREA)
  • Genetics & Genomics (AREA)
  • Biophysics (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Epidemiology (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Analytical Chemistry (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Immunology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Medicinal Preparation (AREA)
SA523440745A 2020-11-13 2023-05-11 (TfR1) ربائط الببتيد ثنائية الحلقة الخاصة بمستقبلات الترانسفيرين 1 SA523440745B1 (ar)

Applications Claiming Priority (4)

Application Number Priority Date Filing Date Title
GBGB2017927.1A GB202017927D0 (en) 2020-11-13 2020-11-13 Bicyclic peptide ligands specific for transferrin
GBGB2106903.4A GB202106903D0 (en) 2021-05-14 2021-05-14 Bicycle peptide ligands specific for transferrin
US202163261820P 2021-09-29 2021-09-29
PCT/GB2021/052927 WO2022101633A1 (en) 2020-11-13 2021-11-12 BICYCLIC PEPTIDE LIGANDS SPECIFIC FOR TRANSFERRIN RECEPTOR 1 (TfR1)

Publications (1)

Publication Number Publication Date
SA523440745B1 true SA523440745B1 (ar) 2024-07-24

Family

ID=81600834

Family Applications (1)

Application Number Title Priority Date Filing Date
SA523440745A SA523440745B1 (ar) 2020-11-13 2023-05-11 (TfR1) ربائط الببتيد ثنائية الحلقة الخاصة بمستقبلات الترانسفيرين 1

Country Status (13)

Country Link
US (3) US11970555B2 (cg-RX-API-DMAC7.html)
EP (1) EP4244235A1 (cg-RX-API-DMAC7.html)
JP (1) JP7848202B2 (cg-RX-API-DMAC7.html)
KR (1) KR20230107589A (cg-RX-API-DMAC7.html)
CN (1) CN116802190A (cg-RX-API-DMAC7.html)
AR (1) AR126029A1 (cg-RX-API-DMAC7.html)
AU (1) AU2021376917A1 (cg-RX-API-DMAC7.html)
CA (1) CA3201414A1 (cg-RX-API-DMAC7.html)
IL (1) IL302713A (cg-RX-API-DMAC7.html)
MX (1) MX2023005624A (cg-RX-API-DMAC7.html)
SA (1) SA523440745B1 (cg-RX-API-DMAC7.html)
TW (1) TWI921406B (cg-RX-API-DMAC7.html)
WO (1) WO2022101633A1 (cg-RX-API-DMAC7.html)

Families Citing this family (5)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
CN116802190A (zh) 2020-11-13 2023-09-22 拜斯科技术开发有限公司 特异于转铁蛋白受体1(TfR1)的双环肽配体
GB202206431D0 (en) * 2022-05-03 2022-06-15 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)
KR20260021596A (ko) * 2023-04-05 2026-02-13 아이오니스 파마수티컬즈, 인코포레이티드 Pln 발현을 감소시키는 화합물 및 방법
EP4788689A1 (en) 2023-10-03 2026-08-12 BicycleTx Limited Bicyclic peptide ligand complexes specific for tfr1
GB202316970D0 (en) * 2023-11-06 2023-12-20 Bicycletx Ltd Bicyclic peptide ligands specific for transferrin receptor 1 (TfR1)

Family Cites Families (14)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP6074574B2 (ja) 2008-02-05 2017-02-08 バイシクル セラピューティクス リミテッド 方法及び組成物
GB0914110D0 (en) 2009-08-12 2009-09-16 Medical Res Council Peptide libraries
CA2967830A1 (en) * 2014-11-14 2016-05-19 Ossianix, Inc. Tfr selective binding compounds and related methods
CN104650186A (zh) 2015-03-09 2015-05-27 中国药科大学 一种能够与TfR1特异性结合的活性肽及其应用
CA2990785C (en) * 2015-06-24 2024-11-12 Jcr Pharmaceuticals Co., Ltd. ANTI-HUMAN TRANSFERRIN RECEPTOR ANTIBODIES CROSSING THE BLOOD-BRAIN BARRIER
GB201706477D0 (en) 2017-04-24 2017-06-07 Bicycle Therapeutics Ltd Modification of polypeptides
EP3615550A1 (en) 2017-04-27 2020-03-04 BicycleTx Limited Bicyclic peptide ligands and uses thereof
JP7670481B2 (ja) 2017-08-04 2025-04-30 バイスクルテクス・リミテッド Cd137に対して特異的な二環式ペプチドリガンド
CA3080351A1 (en) 2017-11-02 2019-05-09 Ossianix, Inc. Improved tfr-selective binding peptides capable of crossing the blood brain barrier
CA3091775A1 (en) * 2018-02-23 2019-08-29 Bicycletx Limited Multimeric bicyclic peptide ligands
WO2020084305A1 (en) 2018-10-23 2020-04-30 Bicycletx Limited Bicyclic peptide ligands and uses thereof
EP3897849A1 (en) * 2018-12-21 2021-10-27 BicycleTx Limited Bicyclic peptide ligands specific for pd-l1
GB201912320D0 (en) * 2019-08-28 2019-10-09 Bicycletx Ltd PBP Binding Bicyclic Peptide Ligands
CN116802190A (zh) 2020-11-13 2023-09-22 拜斯科技术开发有限公司 特异于转铁蛋白受体1(TfR1)的双环肽配体

Also Published As

Publication number Publication date
KR20230107589A (ko) 2023-07-17
JP2023549229A (ja) 2023-11-22
IL302713A (en) 2023-07-01
AU2021376917A1 (en) 2023-06-29
AU2021376917A9 (en) 2024-09-12
CA3201414A1 (en) 2022-05-19
US20240391959A1 (en) 2024-11-28
MX2023005624A (es) 2023-05-24
TWI921406B (zh) 2026-04-11
WO2022101633A1 (en) 2022-05-19
AR126029A1 (es) 2023-09-06
US20220194988A1 (en) 2022-06-23
EP4244235A1 (en) 2023-09-20
JP7848202B2 (ja) 2026-04-20
TW202233664A (zh) 2022-09-01
US20250340595A1 (en) 2025-11-06
US11970555B2 (en) 2024-04-30
CN116802190A (zh) 2023-09-22

Similar Documents

Publication Publication Date Title
MX2021013669A (es) Ligandos peptidicos biciclicos especificos para ox40.
PH12020552179A1 (en) Bicyclic peptide ligands specific for nectin-4
MX2023005624A (es) Ligandos peptidicos biciclicos especificos para el receptor de transferrina 1 (tfr1).
SA520420008B1 (ar) جزيئات ترابطية ببتيدية ثنائية الحلقات متعددة الوحدات
SA520412268B1 (ar) EphA2 مركبات ترابطية من ببتيدات ثنائية الحلقة خاصة بـ
SA522431587B1 (ar) مــركب ببتيد ثنائي الحلقة متغاير الترادف
WO2022148974A3 (en) Bicyclic peptide ligands specific for nk cells
MX2023008168A (es) Complejos peptidicos biciclicos heterotandem.
UA95996C2 (ru) Пегилированный fab-фрагмент антитела, который специфически связывается с бета-амилоидным пептидом
PH12014500902A1 (en) Hla-a* 1101-restricted wt1 peptide and pharmaceutical composition comprising the same
HRP20010877B1 (hr) Pripravci za prevenciju i liječenje amiloidogenskih bolesti
WO2020132366A4 (en) T-cell modulatory multimeric polypeptides with conjugation sites and methods of use thereof
RU2017145014A (ru) Усеченные полипептиды фактора фон виллебранда для лечения гемофилии
JP2015501822A5 (cg-RX-API-DMAC7.html)
JP2023549229A5 (cg-RX-API-DMAC7.html)
CN115605513A (zh) 一种抗pd-l1和her2的双特异性抗体
WO2021074695A8 (en) PD-L1 INHIBITOR - TGFβ INHIBITOR BISPECIFIC DRUG MOIETIES.
JP7133225B2 (ja) 治療用多標的コンストラクトおよびその使用
JP2020501513A5 (cg-RX-API-DMAC7.html)
WO2005058358B1 (en) Use of agents derived from ceacam1 for the treatment of inflammatory diseases
Greindl et al. AGEM400 (HES), a novel erythropoietin mimetic peptide conjugated to hydroxyethyl starch with excellent in vitro efficacy
CN116589592A (zh) 一种降解pd-l1溶酶体靶向超分子内旋肽
EA202190105A1 (ru) Бициклические пептидные лиганды, специфичные к нектину-4
EA202191660A1 (ru) Бициклические пептидные лиганды, специфичные к mt1-mmp
WO2019204402A1 (en) Compositions and methods for treatment of cancer